Passage Bio to Merge with Remix Therapeutics in Reverse Merger, Existing Shareholders to Own 7%
PASG sits 31% above its 52-week low of $3.935 on elevated volume (9.3× avg).
Summary
Passage Bio announced a definitive reverse merger agreement with private company Remix Therapeutics, which includes a $100M+ private placement, providing a cash runway into 2028 but resulting in significant dilution for existing Passage Bio shareholders who will own only 7% of the combined entity.
Key Events · M&A and Partnerships · PASG
-
Definitive Merger Agreement
Passage Bio will merge with private company Remix Therapeutics in an all-stock reverse merger, expected to close in Q4 2026.
-
Significant Shareholder Dilution
Pre-merger Passage Bio shareholders are expected to own approximately 7% of the combined company, reflecting substantial dilution.
-
New Capital and Extended Runway
A concurrent oversubscribed private placement of over $100 million will provide the combined company with a cash runway into 2028.
-
New Clinical Pipeline
The combined entity gains Remix's RNA processing platform and lead program REM-422, which is in a registrational study for adenoid cystic carcinoma.
Analysis · PASG · Life Sciences
This merger is a critical survival strategy for Passage Bio, which recently issued a going concern warning and underwent massive layoffs. While it prevents a likely collapse, existing shareholders face extreme dilution, retaining only 7% ownership. The transaction brings in a new clinical pipeline from Remix and substantial capital, extending the company's financial runway into 2028.
At the time of this filing, PASG was trading at $5.15 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $18.9M. The 52-week trading range was $3.94 to $20.00. This filing was assessed with negative market sentiment and an importance score of 10 out of 10.